Zivo Bioscience Inc
ZIVO
Get informed when a big investor buys or sells
+ FollowMarket Cap$15.55M
Close$
$-0.54
113.4% downside
Current Fair Value
113.4% downsideOvervalued by 113.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $15.55 Million |
|---|---|
| Enterprise Value | $16.32 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.59 |
| Beta | 0.11 |
| Outstanding Shares | 4,001,608 |
Return
| Return on Equity | 193.68% |
|---|---|
| Return on Assets | -1283.44% |
| Return on Invested Capital | 203.35% |
Valuation & Multiples
| P/E Ratio | -2.34 |
|---|---|
| PEG | 3.02 |
| Price to Sales | - |
| Price to Book Ratio | -4.0 |
| Enterprise Value to Revenue | 137.13 |
| Enterprise Value to EBIT | -2.48 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | -0.23 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 3, 2026
EPS Estimate
$-0.30
Average shareholder expectationRevenue Estimate
$125,000
Average shareholder expectationNext Earnings Call
Expected Date
September 2, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$202,000
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Zivo Bioscience Inc
8 employees
CEO: Andrew Dahl